ImageneBio (IMA) Free Cash Flow (2020 - 2025)
ImageneBio (IMA) posted Free Cash Flow of -$26.6 million for Q3 2025, down 294.46% sequentially from -$6.8 million in Q2 2025, and down 305.54% YoY from $13.0 million in Q3 2024.
ImageneBio (IMA) Free Cash Flow (2020 - 2025) Analysis & Trends
ImageneBio has reported Free Cash Flow for 6 years, with the latest figure at -$26.6 million in Q3 2025.
- Quarterly Free Cash Flow fell 305.54% year-over-year to -$26.6 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$40.6 million (up 11.69% YoY) and the FY2024 annual result came in at -$46.0 million, up 42.61% from the prior year.
- Free Cash Flow slipped to -$26.6 million in Q3 2025 per IMA's latest filing, from -$6.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $13.0 million in Q3 2024 and troughed at -$28.2 million in Q4 2024.
- A 5-year average of -$16.0 million and a median of -$18.1 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 164.82% in 2024, then plunged 305.54% in 2025.
- Over 5 years, Free Cash Flow stood at -$13.9 million in 2021, then declined by 28.51% to -$17.9 million in 2022, then fell by 23.45% to -$22.1 million in 2023, then fell by 27.53% to -$28.2 million in 2024, then increased by 5.39% to -$26.6 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$26.6 million, -$6.8 million, and -$7.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - | 477.44 Mn |
| 10 | ImageneBio | 47.41 Mn | -87.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -26.64 Mn |
| Sep 30, 2025 | -26.64 Mn |
| Jun 30, 2025 | -6.75 Mn |
| Jun 30, 2025 | -6.75 Mn |
| Mar 31, 2025 | -7.23 Mn |
| Mar 31, 2025 | -7.23 Mn |
| Dec 31, 2024 | -28.16 Mn |
| Dec 31, 2024 | -28.16 Mn |
| Sep 30, 2024 | 12.96 Mn |
| Sep 30, 2024 | 12.96 Mn |
| Jun 30, 2024 | -12.50 Mn |
| Jun 30, 2024 | -12.50 Mn |
| Mar 31, 2024 | -18.30 Mn |
| Mar 31, 2024 | -18.30 Mn |
| Dec 31, 2023 | -22.08 Mn |
| Dec 31, 2023 | -22.08 Mn |
| Sep 30, 2023 | -20.00 Mn |
| Sep 30, 2023 | -20.00 Mn |
| Jun 30, 2023 | -18.14 Mn |
| Jun 30, 2023 | -18.14 Mn |